From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma
Current Oncology · 01.02.2024 · 31 (2) · 778-800
DOI: 10.3390/curroncol31020058 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 01.02.2024. Verfasst von Kamil J Synoradzki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Environmental Laboratory of Pharmacological and Toxicological Research, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinsk…. Hauptthemen laut MEDLINE: Nanomedicine, Melanoma, Uveal Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Naples Federico II.
Abstract (Originalsprache)
Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells. Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor RNA. Another potential approach to treat UM could be based on T cell receptor engineering rather than antibody modification. Immune-mobilizing monoclonal T cell receptors (TCR) against cancer, called ImmTAC TM molecules, represent such an approach. Moreover, nanomedicine, especially miRNA approaches, are promising for future trials. Finally, theranostic radiopharmaceuticals enabling diagnosis and therapy with the same molecule bring hope to this research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Environmental Laboratory of Pharmacological and Toxicological Research, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego Str., 02-106 Warsaw, Poland.
- Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Str., 02-781 Warsaw, Poland.
- Chair and Department of General and Pediatric Ophthalmology, Medical University of Lublin, 1 Chmielna Str., 20-079 Lublin, Poland.
- Eye Clinic, Public Health Department, Federico II University, Via Pansini 5, 80131 Naples, Italy.
- Research and Development Centre Novasome Sp. z o.o., 51-423 Wrocław, Poland.
ORCID-Profile: Kamil J Synoradzki, Malgorzata Solnik, Mario Damiano Toro, Piotr Rutkowski, Yacoub A Yousef, Claudio Bucolo, Sandrine Anne Zweifel, Michele Reibaldi, Michal Fiedorowicz, Anna M Czarnecka
Förderung
- University of Naples Federico II
Zitieren
APA
Synoradzki, K. J., Paduszyńska, N., Solnik, M., Toro, M. D., Bilmin, K., Bylina, E., Rutkowski, P., Yousef, Y. A., Bucolo, C., Zweifel, S. A., Reibaldi, M., Fiedorowicz, M., & Czarnecka, A. M. (2024). From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma. Current Oncology, 31(2), 778-800. https://doi.org/10.3390/curroncol31020058
Vancouver
Synoradzki KJ, Paduszyńska N, Solnik M, Toro MD, Bilmin K, Bylina E, et al. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma. Current Oncology. 2024;31(2):778-800. doi:10.3390/curroncol31020058
BibTeX
@article{Synoradzki2024,
author = {Synoradzki, Kamil J and Paduszyńska, Natalia and Solnik, Malgorzata and Toro, Mario Damiano and Bilmin, Krzysztof and Bylina, Elżbieta and Rutkowski, Piotr and Yousef, Yacoub A and Bucolo, Claudio and Zweifel, Sandrine Anne and Reibaldi, Michele and Fiedorowicz, Michal and Czarnecka, Anna M},
title = {From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {2},
pages = {778--800},
doi = {10.3390/curroncol31020058}
}
EUVIMED